Raloxifene versus continuous combined estrogen/progestin therapy: Densitometric and biochemical effects in healthy postmenopausal Taiwanese women

We treated 116 healthy postmenopausal women (age 47-66 years, mean 57 years) in Taiwan with either raloxifene (RLX) 60 mg (n = 92) or 0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate (CCEP, n = 24) daily for 12 months in a randomized, double-masked, active-controlled fashion. The results showed that both regimens increased bone mineral density (BMD) at hip bip sites (means: RLX 2.5-4.9%, CCEP 4.6-7.9%, all p < 0.005 compared with baseline), and the difference between the two regimens was not significant. The spinal BMD increased significantly in both groups (1.4% with RLX and 6.0% with CCEP, both p < 0.01), and more with CCEP (p < 0.003). Osteocalcin levels and urinary type I collagen C-telopeptide/creatinine ratios decreased significantly in both regimens, but the decreases were significantly larger with CCEP. Compared with baseline, both RLX and CCEP decreased the total cholesterol (median 4.9% and 8.6% respectively, p < 0.001) and LDL-cholesterol (median 11% and 19% respectively, p < 0.001), and increased HDL-cholesterol (median 8.6% and 10.7% respectively, p < 0.01). Both regimens increased triglyceride levels (median 3.2% and 18.9% respectively, both p < 0.05), although to a lesser extent with RLX than with CCEP (p < 0.05). Only 3 subjects (3.3%) reported vaginal bleeding in the RLX group, as compared with 31% (7/22) with CCEP (p < 0.05). We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP.